Abstract
70P Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have